author-photo

Shankara Paneesha

University Hospitals Birmingham NHS Foundation Trust

10

Papers

15

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Adenoviral Subacute Focal Meningoencephalitis Complicating Polatuzumab, Bendamustine and Rituximab Chemo-Immunotherapy for Aggressive B-Cell Lymphoma

2021 Indian Journal of Hematology and Blood Transfusion
Show All
- Source
- Cite
- Save
Citations (0)
Vaccine Efficacy after Rituximab Exposure: First Interim Analysis of Virtue Project on Behalf of West Midlands Research Consortium, UK

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations.

2021 Case reports in hematology
Show All
- Source
- Cite
- Save
Citations (0)
IBCL-131: inMIND: A Phase 3 Study of Tafasitamab + Lenalidomide Add-On to Rituximab vs Placebo + Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
INMIND: A PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND RITUXIMAB VS PLACEBO + LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia.

2019 Frontiers in Immunology
Show All
- Source
- Cite
- Save
Citations (15)